drug
difelikefalin
Marketedupdated 5mo agoby Vifor Pharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying difelikefalin
- phase2Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
- phase3Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
- phase1Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
- phase3Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
- phase3CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- phase3A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- phase3Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
- phase2Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 12, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Nov 12, 2027compositionUS 100175361.1y
- Nov 12, 2027method-of-use (U-3204)US 101382701.1y
- Nov 12, 2027compositionUS 107935961.1y
- Nov 12, 2027compositionUS 74025641.1y
- Nov 12, 2027compositionUS 77139371.1y
- Nov 12, 2027compositionUS 77279631.1y
- Nov 12, 2027method-of-use (U-3204)US 82170071.1y
- Nov 12, 2027method-of-use (U-3204)US 82367661.1y
- Nov 12, 2027method-of-use (U-3204)US 84868941.1y
- Nov 12, 2027compositionUS 85361311.1y
- Nov 12, 2027method-of-use (U-3204)US 93343051.1y
- Nov 12, 2027method-of-use (U-3204)US 93593991.1y
FDA exclusivities (1)
- Aug 23, 2026NCENew Chemical Entity (5y)
News(1)
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugAustralia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.fiercebiotech · 1d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that